Updated:
Immuneering Corporation
Immuneering Corp uses a computational biology platform to develop oncology drugs for RAS-mutant cancers, led by co-founders Ben Zeskind and Brett Hall.
Immuneering Corporation
Immuneering Corporation was founded in 2008 by Ben Zeskind and Brett Hall, pivoting from big-data analytics into drug development after a decade of refining its Disease Cancelling Technology. The firm occupies the intersection of machine learning and translational medicine, using public record filings and grant history to trace its evolution from a consultancy into a publicly traded biotechnology entity focused on solid tumors. Strategy hinges on a single computational platform rather than a diverse therapeutic focus. Immuneering applies its algorithms to identify disease-causing signaling pathways and designs small molecules to neutralize them. The pipeline is anchored by IMM-1-104, a dual-MEK inhibitor for advanced solid tumors harboring RAS mutations, which entered Phase 1/2a trials in 2022. A second program, IMM-6-415, targets Class II BRAF-mutant MAPK-driven cancers. The firm does not operate as a fund; it deploys capital internally from its Nasdaq listing (ticker: IMRX) and a 2021 IPO that raised roughly $114 million. Pre-IPO, the company secured Series A and B rounds with participation from Boxcar PMJ, Sphera Healthcare, and other institutional investors. Its geographic footprint is concentrated in Cambridge, Massachusetts, with trial sites extending across the United States and Australia. Scale is measured by pipeline depth and market capitalization rather than assets under management. Immuneering reported 84 full-time employees in its 2022 annual filing. The Eli Lilly deal, struck in May 2021, granted Immuneering a portfolio of CNS assets in exchange for equity and milestones, a transaction that validated the platform's out-licensing appeal. The company's 2023 restructuring reduced headcount by approximately 15%, refocusing resources entirely toward its lead oncology programs. Structural differentiation rests in a dual engine: a proprietary discovery platform that the firm asserts can model drug effects across thousands of disease states simultaneously, and a public-company treasury that funds development through equity raises. No family office or fund structure underpins the entity; it competes with clinical-stage biotechs like Relay Therapeutics for computational-drug-design talent while facing the same Phase 2 data catalysts that determine survival for any single-asset oncology company.
General information
Firm type
Asset Manager
Year founded
2008
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Cambridge
Corporate office
Cambridge, MA, United States
Principals
Ben Zeskind
Chief Executive Officer & Co-Founder
Brett Hall
Chief Scientific Officer & Co-Founder
Sector focus
Frequently asked questions
What is Immuneering's Disease Cancelling Technology?
The platform uses machine learning trained on multi-omic data to model disease signaling and predict which small-molecule interventions can neutralize a disease pathway while avoiding side effects. Immuneering states the technology identifies treatments that tackle the root cause of cancer rather than downstream symptoms. The firm has published peer-reviewed work in journals including Cancer Research detailing its approach to MEK inhibition.
Who runs the investment and strategic decisions at Immuneering?
Co-founder and CEO Ben Zeskind leads strategic decisions, including capital allocation, partnership structuring, and equity raises. The firm operates as a public biotech company governed by a board of directors that includes representatives from its institutional shareholders. All investment in the platform is funded through public equity markets, not a closed fund structure.
What investment stages does Immuneering participate in?
Immuneering is not a fund and does not invest in external companies. It is a clinical-stage biotechnology company that finances its own drug development through Nasdaq equity raises. Its only 'portfolio' is its internal pipeline. The firm has historically licensed its platform to partners like Eli Lilly, which constituted a revenue stream rather than a co-investment.
How does Immuneering source its drug candidates?
Drug candidates originate entirely from the firm's own computational platform, which sifts through biological data to nominate targets. The platform-driven strategy means the pipeline is generated in-house, not acquired from universities or other biotechs. The 2021 Eli Lilly transaction brought CNS compounds into the firm, but these were subsequently deprioritized in 2023 to focus on internal oncology programs.
Is Immuneering structured as a family office or venture firm?
No. Immuneering is a publicly traded biotech corporation listed on Nasdaq under the ticker IMRX. It raises capital through equity offerings and grants, not by managing third-party assets or family wealth. Its corporate structure includes R&D units, a clinical operations team, and a standard biotech governance framework.
Which sectors does Immuneering explicitly avoid?
Following a 2023 restructuring, Immuneering suspended work on central nervous system programs it acquired from Eli Lilly. The firm is now exclusively focused on oncology, specifically RAS/MAPK pathway-driven solid tumors. Immunology, rare disease, and non-oncology indications are outside its stated focus.
What is Immuneering's known capital-raising history?
The firm raised a $17 million Series A in 2019 and a $62 million Series B in 2020 led by Boxcar PMJ. It went public on Nasdaq in July 2021, raising approximately $114 million in gross proceeds. As a public company with no recurring revenue, it funds operations through periodic equity offerings and grant income (per the firm's SEC filings, 2021-2023).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: